TiumBio Officially Invited to Participate in JP Morgan Healthcare Conference

Tium Bio announced on the 5th that it has been officially invited to participate in the '2024 JP Morgan Healthcare Conference.'

The JP Morgan Healthcare Conference (JPMHC), held from the 8th to the 11th in San Francisco, California, USA, is known as the world's largest pharmaceutical and biotech investment conference. It is expected to gather 600 companies and over 8,000 investment industry professionals.

Tium Bio's CEO Kim Hoon-taek and Head of Business Development Yoon Seok-won will visit the site to engage with global big pharma companies. They will seek partners for new drugs such as 'Marigoldix (TU2670),' a uterine fibroids and endometriosis treatment currently in the final stages of clinical trials, and 'TU2218,' an oral immuno-oncology drug. Additionally, they plan to attend the 'Bio Partnering at JPM Week,' an event linked to JPMHC, to expand business development opportunities with potential partners.

Kim Hoon-taek, CEO of Tium Bio, said, “Starting well with JPMHC, we will do our best to deliver successful clinical results and business development achievements this year.”